Haemonetics Future Growth
Future criteria checks 4/6
Haemonetics is forecast to grow earnings and revenue by 24.7% and 6.2% per annum respectively. EPS is expected to grow by 25.3% per annum. Return on equity is forecast to be 25% in 3 years.
Key information
24.7%
Earnings growth rate
25.3%
EPS growth rate
| Medical Equipment earnings growth | 17.1% |
| Revenue growth rate | 6.2% |
| Future return on equity | 25.0% |
| Analyst coverage | Good |
| Last updated | 15 Nov 2024 |
Recent future growth updates
Recent updates
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
Aug 14Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Jul 18Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Apr 30Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains
Aug 09Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors
Aug 09An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued
Jul 25Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?
Mar 19Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Feb 16Haemonetics: Earnings Rate Of Change Justifies High Multiples
Feb 01We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?
Dec 15Haemonetics Q2 2023 Earnings Preview
Nov 04Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy
Sep 06Haemonetics reaches new 52-week high; shares up 41% YTD
Aug 24Haemonetics reports Q2 earnings beat; raises FY22 guidance
Aug 10A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)
Aug 10Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly
Jul 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 1,579 | 267 | N/A | N/A | 6 |
| 3/31/2026 | 1,456 | 221 | N/A | N/A | 10 |
| 3/31/2025 | 1,395 | 177 | N/A | N/A | 10 |
| 9/28/2024 | 1,361 | 124 | 31 | 85 | N/A |
| 6/29/2024 | 1,334 | 115 | 69 | 135 | N/A |
| 3/30/2024 | 1,309 | 118 | 115 | 182 | N/A |
| 12/30/2023 | 1,270 | 127 | 129 | 197 | N/A |
| 9/30/2023 | 1,239 | 128 | 199 | 262 | N/A |
| 7/1/2023 | 1,219 | 137 | 176 | 250 | N/A |
| 4/1/2023 | 1,169 | 115 | 163 | 273 | N/A |
| 12/31/2022 | 1,129 | 96 | 128 | 261 | N/A |
| 10/1/2022 | 1,084 | 86 | 116 | 260 | N/A |
| 7/2/2022 | 1,026 | 68 | 88 | 216 | N/A |
| 4/2/2022 | 993 | 43 | 76 | 172 | N/A |
| 1/1/2022 | 953 | 23 | 33 | 106 | N/A |
| 10/2/2021 | 934 | 31 | 54 | 110 | N/A |
| 7/3/2021 | 903 | 64 | 52 | 95 | N/A |
| 4/3/2021 | 870 | 79 | 72 | 109 | N/A |
| 12/26/2020 | 884 | 108 | 118 | 154 | N/A |
| 9/26/2020 | 903 | 106 | 120 | 167 | N/A |
| 6/27/2020 | 946 | 96 | 119 | 167 | N/A |
| 3/28/2020 | 988 | 77 | 109 | 158 | N/A |
| 12/28/2019 | 999 | 80 | 81 | 132 | N/A |
| 9/28/2019 | 988 | 68 | 51 | 111 | N/A |
| 6/29/2019 | 977 | 49 | 39 | 139 | N/A |
| 3/30/2019 | 968 | 55 | 40 | 159 | N/A |
| 12/29/2018 | 952 | 46 | 72 | 196 | N/A |
| 9/29/2018 | 939 | 21 | 82 | 204 | N/A |
| 6/30/2018 | 922 | 23 | N/A | 205 | N/A |
| 3/31/2018 | 904 | 46 | N/A | 220 | N/A |
| 12/30/2017 | 898 | -17 | N/A | 197 | N/A |
| 9/30/2017 | 892 | 4 | N/A | 187 | N/A |
| 7/1/2017 | 887 | 4 | N/A | 167 | N/A |
| 4/1/2017 | 886 | -26 | N/A | 160 | N/A |
| 12/31/2016 | 900 | 16 | N/A | 178 | N/A |
| 10/1/2016 | 906 | -59 | N/A | 155 | N/A |
| 7/2/2016 | 905 | -66 | N/A | 143 | N/A |
| 4/2/2016 | 909 | -56 | N/A | 122 | N/A |
| 12/26/2015 | 893 | -50 | N/A | 124 | N/A |
| 9/26/2015 | 891 | 26 | N/A | 119 | N/A |
| 6/27/2015 | 899 | 20 | N/A | 123 | N/A |
| 3/28/2015 | 910 | 17 | N/A | 127 | N/A |
| 12/27/2014 | 925 | 30 | N/A | 123 | N/A |
| 9/27/2014 | 935 | 30 | N/A | 142 | N/A |
| 6/28/2014 | 943 | 39 | N/A | 140 | N/A |
| 3/29/2014 | 939 | 35 | N/A | 140 | N/A |
| 12/28/2013 | 947 | 38 | N/A | 116 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HAE's forecast earnings growth (24.7% per year) is above the savings rate (2.6%).
Earnings vs Market: HAE's earnings (24.7% per year) are forecast to grow faster than the US market (15.3% per year).
High Growth Earnings: HAE's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HAE's revenue (6.2% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: HAE's revenue (6.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HAE's Return on Equity is forecast to be high in 3 years time (25%)